Differential effects of erufosine on proliferation, wound healing and apoptosis in colorectal cancer cell lines

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1407-1416

  Kaleaǧasioǧlu, Ferda ^a   Berger, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Collagen; Colorectal cancer cell lines; Erufosine; Osteonectin; Wound healing

Indexed keywords

ANTIMITOTIC AGENT; CASPASE 3; CASPASE 7; ERUFOSINE; OSTEONECTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL RATE; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN TYPE I; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION; HUMANS; ORGANOPHOSPHATES; OSTEONECTIN; QUATERNARY AMMONIUM COMPOUNDS; RATS;

EID: 84896717524     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2942     Document Type: Article

References (59)

1. Lozano R, Naghavi M, Foreman K, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095-2128, 2012.
2. Siegel R, Naishadham D and Jemal A: Cancer Statistics 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G and Piedbois P: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 356: 373-378, 2000. (Pubitemid 30487493)
4. Hoff PM, Ansari R, Batist G, et al : Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292, 2001. (Pubitemid 32366981)
5. Porschen R, Arkenau HT, Kubicka S, et al: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223, 2007. (Pubitemid 47548561)
6. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786, 2007.
7. de Gramont A, Figer A, Seymour M, et al : Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
8. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
9. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875, 2005. (Pubitemid 46223991)
10. Díaz-Rubio E, Tabernero J, Gómez-España A, et al: Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25: 4224-4230, 2007. (Pubitemid 47548562)
11. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572, 2009.
12. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664, 2007. (Pubitemid 46797944)
13. Kubicka S, Greil R, André T, et al: Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol 24: 2342-2349, 2013.
14. Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499-3506, 2012.
15. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019, 2008.
16. Hilgard P, Klenner T, Stekar J and Unger C: Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 32: 90-95, 1993. (Pubitemid 23131925)
17. Berkovic D: Cytotoxic ether-phospholipid analogues. Gen Pharmacol 31: 511-517, 1998.
18. Vink SR, van Blitterswijk WJ, Schellens JHM and Verheij M: Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat Rev 33: 191-202, 2007. (Pubitemid 46323398)
19. Van Blitterswijk WJ and Verheij M: Anticancer mechanisms and clinical application of alkylphospholipids. Biochim Biophys Acta 1831: 663-674, 2013.
20. Yosifov DY, Todorov PT, Zaharieva MM, Georgiev KD, Pilicheva BA, Konstantinov SM and Berger MR: Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemother Pharmacol 67: 13-25, 2011.
21. Georgieva MC, Konstantinov SM, Topashka-Ancheva M and Berger MR: Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Lett 182: 163-174, 2002. (Pubitemid 34621180)
22. Bagley RG, Kurtzberg L, Rouleau C, Yao M and Teicher BA: Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells. Cancer Chemother Pharmacol 68: 1537-1546, 2011.
23. Zaharieva MM, Konstantinov SM, Pilicheva B, Karaivanova M and Berger MR: Erufosine - a membrane targeting antineoplastic agent with signal transduction modulating effects. Ann NY Acad Sci 1095: 182-192, 2007. (Pubitemid 47092450)
24. Fiegl M, Lindner LH, Juergens M, Eibl H, Hiddemann W and Braess J: Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother Pharmacol 62: 321-329, 2008. (Pubitemid 351692092)
25. Martelli AM, Papa V, Tazzari PL, et al: Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia 24: 687-698, 2010.
26. Königs SK, Pallascha CP, Lindnerb LH, et al: Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway. Leuk Res 34: 1064-1069, 2010.
27. Yosifov DY, Reufsteck C, Konstantinov SM and Berger MR: Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines. Leuk Res 36: 764-772, 2012.
28. Konstantinov SM and Berger MR: Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines. Cancer Lett 144: 153-160, 1999. (Pubitemid 29457657)
29. Dineva IK, Zaharieva MM, Konstantinov SM, Eibl H and Berger MR: Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins. J Cancer Res Clin Oncol 138: 1909-1917, 2012.
30. Kapoor V, Zaharieva MM, Das SN and Berger MR: Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma. Cancer Lett 319: 39-48, 2012.
31. Lemeshko VV and Kugler W: Synergistic inhibition of mitochondrial respiration by anticancer agent erucylphosphohomocholine and cyclosporin A. J Biol Chem 282: 37303-37307, 2007.
32. Rübel A, Handrick R, Lindner LH, et al: The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol 1: 6, 2006.
33. Veenman L, Alten J, Linnemannstöns K, et al: Potential involvement of F0F1-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines: a mechanism for induction of apoptosis via the 18 kDa mitochondrial translocator protein. Apoptosis 15: 753-768, 2010.
34. Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C and Jendrossek V: The Akt-inhibitor erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol 5: 108, 2010.
35. Berger MR, Tsoneva I, Konstantinov SM and Eibl H: Induction of apoptosis by erucylphospho-N,N, N-trimethylammonium is associated with changes in signal molecule expression and location. Ann NY Acad Sci 1010: 307-310, 2003. (Pubitemid 38264995)
36. Sobottka SB and Berger MR: Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties. Cancer Chemother Pharmacol 30: 385-393, 1992.
37. Sobottka SB, Berger MR and Eibl H: Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo. Int J Cancer 53: 418-425, 1993. (Pubitemid 23047889)
38. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
39. Liang CC, Park AY and Guan JL: In vitro scratch assay: a convenient and inexpensive method or analysis of cell migration in vitro. Nat Protoc 2: 329-333, 2007. (Pubitemid 47040047)
40. Rothbarth J, Koevoets C, Tollenaar RA, Tilby MJ, van de Velde CJ, Mulder, GJ and Kuppen PJ: Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo. Biochem Pharmacol 67: 1771-1778, 2004. (Pubitemid 38479855)
41. Haynes RH, Eckardt F and Kunz BA: The DNA damage-repair hypothesis in radiation biology: comparison with classical hit theory. Br J Cancer 49: 81-90, 1984. (Pubitemid 14130898)
42. Orr JS: Concepts, problems and the role of modifying agents in the relationship between recovery of cells' survival ability and mechanisms of repair of radiation lesions. Br J Cancer (Suppl) 49: 1-6, 1984.
43. Hall EJ and Brenner DJ: Radiobiology of low- and high-dose-rate brachytherapy. In: Technical Basis of Radiation Therapy. 4th edition. Levitt SH, Purdy JA, Perez CA and Vijayakumar S (eds). Springer Verlag, Berlin, pp291-307, 2008.
44. Miura K, Fujibuchi W, Ishida K, et al: Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today 41: 175-182, 2011.
45. Georges RB, Adwan H, Hamdi H, Hielscher T, Linnemann U and Berger MR: The insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis. Cancer Biol Ther 12: 69-79, 2011.
46. Kawamura M, Toiyama Y, Tanaka K, et al: CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer 48: 2244-2251, 2012.
47. Kabra N, Li Z, Chen L, et al: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 284: 18210-18217, 2009.
48. Yosifov DY, Dineva IK, Zaharieva MM, Konstantinov SM and Berger MR: The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium (ErPC3). Cancer Biol Ther 6: 930-935, 2007. (Pubitemid 351574984)
49. DeGregori J: The Rb network. J Cell Sci 117: 3411-3413, 2004.
50. Kugler W, Buchholz F, Köhler F, Eibl H, Lakomek M and Erdlenbruch B: Downregulation of Apaf-1 and caspase-3 by RNA interference in human glioma cells: consequences for erucylphosphocholine-induced apoptosis. Apoptosis 10: 1163-1174, 2005. (Pubitemid 41285591)
51. Yang SY, Bolvin C, Sales KM, Fuller B, Seifalian AM and Winslet MC: IGF-I activates caspases 3/7, 8 and 9 but does not induce cell death in colorectal cancer cells. BMC Cancer 9: 158, 2009.
52. Nhan TQ, Liles WC and Schwartz SM: Physiological functions of caspases beyond cell death. Am J Pathol 169: 729-737, 2006. (Pubitemid 44411940)
53. Bröker LE, Kruyt FAE and Giaccone G: Cell death independent of caspases: a review. Clin Cancer Res 11: 3155-3162, 2005. (Pubitemid 40627860)
54. Naumann U, Wischhusen J, Weit S, Rieger J Wolburg H, Massing U and Weller M: Alkylphosphocholine-induced glioma cell death is BCL-XL-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation. Cell Death Differ 11: 1326-1341, 2004. (Pubitemid 39591778)
55. Eibl, KH, Kook D, Priglinger S, Haritoglou C, Yu A, Kampik A and Welge-Lussen U: Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by alkylphosphocholines. Invest Ophthalmol Vis Sci 47: 364-370, 2006. (Pubitemid 46780837)
56. Hendriks T, Martens MF, Huyben CM and Wobbes T: Inhibition of basal and TGFJ-induced fibroblast collagen synthesis by anti-neoplastic agents. Implications for wound healing. Br J Cancer 67: 545-550, 1993. (Pubitemid 23077650)
57. Louneva N, Saitta B, Herrick DJ and Jimenez SA: Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743. J Biol Chem 278: 40400-40407, 2003. (Pubitemid 37248609)
58. Seet LF, Su R, Toh LZ and Wong TT: In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon's fibroblasts: comparisons with mitomycin C. J Cell Mol Med 16: 1245-1259, 2012.
59. Auman JT and McLeod HL: Colorectal cancer cell lines lack the molecular heterogeneity of clinical colorectal tumors. Clin Colorectal Cancer 9: 40-47, 2010.